TMCnet News
Research and Markets: IL-5 Signaling Pathway in Oncology Drug Pipeline Report 2015Research and Markets (http://www.researchandmarkets.com/research/8gzk57/il5_signaling) has announced the addition of the "IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering. The IL-5 signaling pathway activates the JAK/STAT and Raf/MAPK signaling modules. There are today 128 companies plus partners developing 156 IL-5 pathway targeting drugs in 710 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to anther 81 drugs. IL-5 Signaling Pathway in Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 142 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 139 out of the 141 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 31 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath. Pipeline Breakdown According to Number of Drugs
Delivery Format: Desktop App plus Online Access to Updates (One Year) For more information visit http://www.researchandmarkets.com/research/8gzk57/il5_signaling
|
